Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
We utilise our cutting-edge, exclusive workflow to develop focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
Q9BXR6
UPID:
FHR5_HUMAN
Alternative names:
-
Alternative UPACC:
Q9BXR6; Q2NKK2
Background:
Complement factor H-related protein 5 (CFHR5) plays a pivotal role in complement regulation. Its dimerized forms exhibit strong affinity for tissue-bound complement fragments, effectively competing with the physiological complement inhibitor CFH. This unique mechanism underscores its significance in maintaining complement homeostasis.
Therapeutic significance:
CFHR5 deficiency is a progressive disease marked by severe renal impairments such as glomerulonephritis, hematuria, and ultimately, end-stage renal disease. The disease's link to mutations in the CFHR5 gene highlights the protein's critical role in renal health and disease, suggesting that targeting CFHR5 pathways could offer novel therapeutic avenues.